Former Coupa CPO Michael Van Keulen Joins Flywl as Strategic Advisor
SAN FRANCISCO, August 04, 2025--(BUSINESS WIRE)--Flywl, the cloud marketplace platform for enterprise software procurement, is proud to announce that Michael Van Keulen (MVK), former Chief Procurement Officer at Coupa, will join the company as a Strategic Advisor effective August 1.
An industry veteran in the procurement space, MVK brings more than 20 years of experience leading and transforming enterprise procurement. He most recently spent over five years at Coupa, where he supported hundreds of deals and helped shape go-to-market strategies that bridged people, process, and technology. Prior to Coupa, MVK led procurement at Lululemon and held leadership roles at VF Corporation, giving him firsthand insight into the evolving priorities and challenges across the procurement landscape.
Flywl CEO Ankur Srivastava and MVK first met at DPW Amsterdam in 2024. "We sat next to each other by pure chance," said MVK. "Within minutes, I knew Ankur had a bold, compelling vision. That's when I knew I wanted to find a way to work together."
Srivastava echoed the sentiment, "MVK brings a rare combination of experience, credibility, and vision. He's lived the pain points our customers face and he's helped shape the very systems they use today. Having him join Flywl is not just validation of our mission, it's fuel for our momentum. He understands where procurement has been and where it needs to go, and we're lucky to have him helping lead the charge."
MVK's decision to join Flywl reflects his belief that marketplaces and procurement velocity will define the next wave of transformation.
"Procurement teams are under pressure to move fast, deliver value, and reduce administrative drag," said MVK. "Marketplaces promise savings, but are often riddled with complexity. What Flywl is doing, simplifying marketplace buying while maintaining financial control, is exactly what procurement, finance, and IT need. I'm excited to help them build what's next."
About Flywl
Flywl is the cloud marketplace platform built for enterprise software buyers. The company unifies software licensing across AWS, Microsoft Azure, and Google Cloud Marketplace, reducing procurement cycles from months to days while helping buyers maximize existing cloud commitments. Founded in 2024 by former AWS Marketplace leadership, Flywl has raised $7 million in seed funding and is headquartered in San Francisco. Learn more at www.flywl.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250804589506/en/
Contacts
Press Christina FankhanelChristina@attractful.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Philip Morris Stock Outlook: Is Wall Street Bullish or Bearish?
With a market cap of $253.7 billion, Philip Morris International Inc. (PM) is a global tobacco company focused on delivering a smoke-free future. Its product portfolio includes traditional cigarettes, smoke-free alternatives like IQOS and ZYN, and expanding offerings in wellness and healthcare. Shares of the Stamford, Connecticut-based company have outperformed the broader market over the past 52 weeks. PM stock has surged 38.3% over this time frame, while the broader S&P 500 Index ($SPX) has gained 18.4%. Moreover, shares of Philip Morris are up 35.4% on a YTD basis, compared to SPX's 7.6% increase. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, the tobacco giant stock has also outpaced the Consumer Staples Select Sector SPDR Fund's (XLP) 1.6% rise over the past 52 weeks. Despite reporting a better-than-expected Q2 2025 adjusted EPS of $1.91, shares of Philip Morris tumbled 8.4% on Jul. 22. Total sales rose 7.1% to $10.1 billion and ZYN shipments came in at 190 million cans, both missing analysts' estimates. For the fiscal year ending in December 2025, analysts expect PM's adjusted EPS to grow 14.3% year-over-year to $7.51. The company's earnings surprise history is promising. It beat the consensus estimates in the last four quarters. Among the 14 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on nine 'Strong Buy' ratings, two 'Moderate Buys,' and three 'Holds.' On Jul. 14, UBS maintained its 'Neutral' rating on Philip Morris but raised its price target to $181, citing strong smoke-free margin growth driven by IQOS and ZYN, with robust U.S. volume projections and revised earnings estimates through 2027. As of writing, the stock is trading below the mean price target of $193.38. The Street-high price target of $220 implies a potential upside of nearly 35% from the current price. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Finance and foreign ministers in Mexico to talk trade ahead of Carney's visit
OTTAWA — Foreign Affairs Minister Anita Anand and Finance Minister François-Philippe Champagne are in Mexico to meet with President Claudia Sheinbaum to talk economic growth, trade and security. Their trip is happening ahead of Prime Minister Mark Carney's planned visit to Mexico to meet with Sheinbaum. The U.S. hit Canada on Friday with a 35 per cent tariff on goods not compliant with the Canada-United States-Mexico agreement on trade, known as CUSMA, while Mexico received a 90-day reprieve from threatened higher levies. CUSMA is scheduled for a mandatory review next year. Ontario Premier Doug Ford called last year for a bilateral trade deal between Canada and the United States because he said Mexico was serving as a back door for Chinese auto parts and vehicles entering the North American market. Anand and Champagne will also meet with Canadian and Mexican business leaders during the two-day trip. This report by The Canadian Press was first published Aug. 5, 2025. David Baxter, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
